CBER Advanced Manufacturing Extramural Research Contracts
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $250,000 to $700,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- Points of contact
-
- tbd@fda.gov
- Joshua Holliday joshua.holliday@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration (FDA) is forecasting a contract opportunity for extramural research projects focused on advancing manufacturing approaches for biologics regulated by the Center for Biologics Evaluation and Research (CBER). The contract aims to support innovative development and adoption of manufacturing techniques for biological products, with an estimated solicitation release date of July 1, 2026, and a projected award date of September 1, 2026. This opportunity falls under the Biological Product Manufacturing NAICS code 325414 and is not set aside for any specific business category.
While specific award values are not currently detailed, the contract will involve research projects to enhance manufacturing processes for biologics. Interested contractors should contact Joshua Holliday (joshua.holliday@fda.hhs.gov) from the FDA for potential additional information. The point of contact email for general inquiries is currently listed as tbd@fda.gov, suggesting that more specific details about the contract's scope, budget, and performance location will be forthcoming as the solicitation date approaches.
Forecast text
Award contracts to support extramural research projects that promote the development and adoption of innovative approaches for the manufacture of CBER-regulated products.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast